# A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults and Adults With FV Leiden or Prothrombin G20210A Mutation

> **NCT07430397** · PHASE1 · RECRUITING · sponsor: **City Therapeutics** · enrollment: 128 (estimated)

## Conditions studied

- Factor V Leiden
- Prothrombin G20210A

## Interventions

- **DRUG:** CITY-FXI
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07430397
- **Lead sponsor:** City Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-22
- **Primary completion:** 2027-08
- **Final completion:** 2027-10
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07430397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07430397, "A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults and Adults With FV Leiden or Prothrombin G20210A Mutation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07430397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*